Literature DB >> 31933017

Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria.

Diamantis P Kofteridis1, Angeliki M Andrianaki2, Sofia Maraki3, Anna Mathioudaki2, Marina Plataki2, Christina Alexopoulou4, Petros Ioannou2, George Samonis2, Antonis Valachis5.   

Abstract

The present study investigated the clinical course, treatment pattern, prognostic factors, and outcome of patients with pun-drug resistant (PDR) infections. This was a retrospective single-center cohort study including consecutive eligible patients with a PDR infection hospitalized at the University Hospital of Heraklion, Crete, Greece, between January 2010 and June 2018. In total, 65 patients with infections due to PDR gram-negative pathogens were identified. The median age was 64 years (interquartile range, IQR: 45.5-74.5) and the median Charlson comorbidity index 3.0 (IQR: 1.0-5.75). Of the 65 PDR isolates, 31 (48%) were Klebsiella pneumoniae, 28 (43%) Acinetobacter baumannii, and 6 (9%) Pseudomonas aeruginosa. The most common empirical therapy was colistin-based combination (n = 32; 49%), followed by non-colistin, non-tigecycline combination (n = 25; 39%), and carbapenemes + tigecycline (n = 8; 12%). The empirical therapy was effective in 50%, 37.5%, and 8% of patients receiving colistin combination, carbapenemes - tigecycline, and non-colistin, non-tigecycline combination, respectively (p value = 0.003). The infection-related in-hospital mortality was 32% (95% confidence interval, CI: 21-45%). Three factors were significantly associated with infection-related in-hospital mortality in multivariate analysis: Charlson comorbidity index (odds ratio, OR: 1.5, 95% CI: 1.0-2.3, p value = 0.030), prior steroid use (OR: 4.1, 95% CI: 1.0-17.0, p value = 0.049), and empirical treatment with non-colistin, non-tigecycline combination (OR: 7.5; 95% CI: 1.7-32.8, p value = 0.008). Infections due to PDR pathogens are associated with considerable mortality. Our results support the use of colistin and/or tigecycline-based combinations as empirical therapy when infection due to PDR pathogens is suspected.

Entities:  

Keywords:  Acinetobacter baumannii; Colistin; Klebsiella pneumonia; Pan-drug-resistant bacteria; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2020        PMID: 31933017     DOI: 10.1007/s10096-019-03784-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  24 in total

Review 1.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

2.  Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness.

Authors:  Rafael López-Rojas; Michael J McConnell; Manuel Enrique Jiménez-Mejías; Juan Domínguez-Herrera; Felipe Fernández-Cuenca; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

Review 3.  Extremely and pandrug-resistant bacteria extra-deaths: myth or reality?

Authors:  Cédric Abat; Pierre-Edouard Fournier; Marie-Thérèse Jimeno; Jean-Marc Rolain; Didier Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-28       Impact factor: 3.267

4.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

Review 5.  Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis.

Authors:  Philipp P Kohler; Cheryl Volling; Karen Green; Elizabeth M Uleryk; Prakesh S Shah; Allison McGeer
Journal:  Infect Control Hosp Epidemiol       Date:  2017-09-27       Impact factor: 3.254

Review 6.  Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Authors:  Moritz Fritzenwanker; Can Imirzalioglu; Susanne Herold; Florian M Wagenlehner; Klaus-Peter Zimmer; Trinad Chakraborty
Journal:  Dtsch Arztebl Int       Date:  2018-05-21       Impact factor: 5.594

7.  Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii.

Authors:  Rafael López-Rojas; Juan Domínguez-Herrera; Michael J McConnell; Fernando Docobo-Peréz; Younes Smani; María Fernández-Reyes; Luis Rivas; Jerónimo Pachón
Journal:  J Infect Dis       Date:  2011-01-07       Impact factor: 5.226

8.  Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes.

Authors:  C Y Wang; J S Jerng; K Y Chen; K Y Cheng; L N Lee; C J Yu; P R Hsueh; P C Yang
Journal:  Clin Microbiol Infect       Date:  2006-01       Impact factor: 8.067

9.  The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.

Authors:  T Amat; A Gutiérrez-Pizarraya; I Machuca; I Gracia-Ahufinger; E Pérez-Nadales; Á Torre-Giménez; J Garnacho-Montero; J M Cisneros; J Torre-Cisneros
Journal:  Clin Microbiol Infect       Date:  2017-09-29       Impact factor: 8.067

10.  Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.

Authors:  Aristine Cheng; Yu-Chung Chuang; Hsin-Yun Sun; Wang-Huei Sheng; Chia-Jui Yang; Chun-Hsing Liao; Po-Ren Hsueh; Jia-Ling Yang; Ni-Jiin Shen; Jann-Tay Wang; Chien-Ching Hung; Yee-Chun Chen; Shan-Chwen Chang
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

View more
  5 in total

1.  Successful treatment of infective endocarditis due to pandrug-resistant Klebsiella pneumoniae with ceftazidime-avibactam and aztreonam.

Authors:  Majed F Alghoribi; Moayad Alqurashi; Liliane Okdah; Bassam Alalwan; Yahya S AlHebaishi; Abdulmajeed Almalki; Maha A Alzayer; Abdulrahman A Alswaji; Michel Doumith; Mazin Barry
Journal:  Sci Rep       Date:  2021-05-06       Impact factor: 4.379

2.  Mortality of Pandrug-Resistant Klebsiella pneumoniae Bloodstream Infections in Critically Ill Patients: A Retrospective Cohort of 115 Episodes.

Authors:  Matthaios Papadimitriou-Olivgeris; Christina Bartzavali; Alexandra Georgakopoulou; Fevronia Kolonitsiou; Chrisavgi Papamichail; Iris Spiliopoulou; Myrto Christofidou; Fotini Fligou; Markos Marangos
Journal:  Antibiotics (Basel)       Date:  2021-01-15

Review 3.  Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients.

Authors:  Helen Giamarellou; Ilias Karaiskos
Journal:  Antibiotics (Basel)       Date:  2022-07-26

4.  Epidemiology, Outcomes and Resource Utilisation in Patients with Carbapenem Non-susceptible Gram-Negative Bacteria in the UK: A Retrospective, Observational Study (CARBAR UK).

Authors:  Simon D Goldenberg; Andrew R Dodgson; Gavin Barlow; Benjamin J Parcell; Lim Jones; Mahableshwar Albur; A Peter R Wilson; David A Enoch; Aleks Marek; Christianne Micallef; Davide Manissero; Christopher Longshaw; Sara Lopes; Karan Gill
Journal:  Adv Ther       Date:  2022-06-14       Impact factor: 4.070

Review 5.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.